Compare DOLE & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DOLE | DRTS |
|---|---|---|
| Founded | 1851 | 2015 |
| Country | Ireland | Israel |
| Employees | N/A | N/A |
| Industry | Farming/Seeds/Milling | Medical/Dental Instruments |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.3B | 1.4B |
| IPO Year | 2021 | 2021 |
| Metric | DOLE | DRTS |
|---|---|---|
| Price | $13.76 | $12.03 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $17.55 | ★ $20.60 |
| AVG Volume (30 Days) | ★ 1.2M | 563.9K |
| Earning Date | 11-09-2026 | 12-01-2026 |
| Dividend Yield | ★ 2.48% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.00 | N/A |
| Revenue | ★ $9,172,907,000.00 | N/A |
| Revenue This Year | $5.87 | N/A |
| Revenue Next Year | $1.92 | $2,030.30 |
| P/E Ratio | $13.72 | ★ N/A |
| Revenue Growth | ★ 8.23 | N/A |
| 52 Week Low | $12.59 | $3.43 |
| 52 Week High | $16.51 | $15.79 |
| Indicator | DOLE | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 53.91 | 38.04 |
| Support Level | $12.83 | $11.49 |
| Resistance Level | $13.92 | $14.15 |
| Average True Range (ATR) | 0.46 | 0.78 |
| MACD | 0.04 | -0.10 |
| Stochastic Oscillator | 55.77 | 13.66 |
Dole PLC operates in the North American and European markets for fresh fruits and vegetables. The company's segment includes Fresh Fruit; Diversified Fresh Produce - EMEA; Diversified Fresh Produce - Americas and ROW. It generates maximum revenue from the Diversified Fresh Produce - EMEA segment. Diversified Fresh Produce - EMEA segment includes Dole's Irish, Dutch, Spanish, Portuguese, French, Italian, U.K., Swedish, Danish, South African, Eastern European, and Brazilian businesses, the majority of which sell a variety of imported and local fresh fruits and vegetables through retail, wholesale and, in some instances, food service channels across the European marketplace. Geographically, the company operates in United States, Ireland, U.K. Spain, Sweden, and Others.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.